In re: Acetaminophen - ASD-ADHD Products Liability Litigation

Filing 106

FINAL JUDGMENT: Accordingly, it is hereby ORDERED that, for the reasons set forth in the Court's Opinion and Order of December 18, 2023, and in the January 16, 2024 Order to Show Cause, final judgment is entered for defendants under Fed. R. Civ. P. 58 in each case listed in Exhibit 1 to this Order. (AS FURTHER SET FORTH IN THIS ORDER.) (Signed by Judge Denise L. Cote on 2/21/2024) (vfr)

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK
-------------------------------------- X
:
IN RE: Acetaminophen – ASD-ADHD
:
Products Liability Litigation
:
:
This Document Relates To: Cases Listed :
in Exhibit 1
:
-------------------------------------- X

22md3043 (DLC)
22mc3043 (DLC)
FINAL JUDGMENT

DENISE COTE, District Judge:
On December 18, 2023, the defendants’ Rule 702 motions
regarding the plaintiffs’ proposed general causation expert
testimony were granted.

On January 16, this Court issued an

Order to Show Cause why summary judgment should not be entered
in each Member Case of this MDL in which the SFC was served on
or before January 11, 2024.
The January 16 Order also provided that plaintiffs in any
Member Case in which an SFC was served on or after January 12,
2024 shall have 21 days from the date of service to show cause
why summary judgment should not be entered in favor of the
defendants named in that Member Case for failure to 1) present
admissible evidence of general causation; 2) show any error in
the December 17, 2023 Rule 702 Opinion; and/or 3) show why the
December 18, 2023 Rue 702 Opinion does not apply to their Member
Case.
On February 1, 2024, plaintiffs conceded that summary
judgment was proper in each Member Case listed in Exhibit A to

C a s e 1: 2 2- m d- 0 3 0 4 3- D L C

D o c u m e nt 1 4 0 5- 1

Fil e d 0 2/ 1 5/ 2 4

E X HI BI T 1

P a g e 1 of 1 6